Innovation Pharmaceuticals Inc (IPIX)

[LIVED]

The conclusions are slightly different:

2017 - Our results suggest Kevetrin is a promising new drug in AML patients treatment, both in wild type and, even more, in TP53 mutated tumors, through different molecular mechanisms, giving more therapeutic alternatives in the treatment of this disease.

https://library.ehaweb.org/eha/2017/22nd/180680/roberta.napolitano.kevetrin.preclinical.study.of.a.new.compound.in.acute.html

2019 - Our results show kevetrin alters several key genes and cellular metabolism. Along with cellular data, this study could provide a rationale for an experimental trial in AML patients, especially those carrying TP53 mutation who actually have very few therapeutic options.

https://library.ehaweb.org/eha/2019/24th/267712/roberta.napolitano.kevetrin.dampens.myc.expression.and.cellular.metabolism.in.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1